| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TherapeuticsMD, Inc.$2.32
+0.03 (+1.31%)
C 45Pipeline Score Undervalued Pharma · Clinical
Market Cap
24.54 M
EPS
0.02
P/E Ratio
137.66 $
Value Trade
88.44 K
SEC Financials
Q1 2026Dilution Risk
Revenue
724.00 K
Operating CF
944.00 K
Total Assets
37.58 M
Total Liabilities
10.61 M
Equity
26.97 M
D/E Ratio
12,345
6 %
Week
1.92 %
1 Month
-7.42 %
3 Month
12.17 %
6 Month
-96.58 %
5 Year
-99.88 %
All Time
Cash Data
Cash Position
8.42 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
4.89 K
52 Week Range
0.98 - 2.95
% held by Insiders
6.87 %
% held by Institutions
33.96 %
Enterprise Value
21.95 M
Total Shares
11.58 M
Short %
0.62 %
Float Shares
8.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C45
Pipeline Score $134M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored5.5x
rNPV / MCap Top 67%
Micro Cap (rank 300 of 905)
Percentile RankTherapeuticsMD, Inc. carries a moderate pipeline score (45/100), with $1.8B risk-adjusted pipeline value, led by Estradiol in Menopause (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Estradiol Small molecule | Menopause | Phase 3 | NCT02449902 | 54% | $1.6B | COMPLETED | 1,915 | - | - | Sep 1, 2013 | - | Dec 14, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TXMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TXMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TXMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TXMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TXMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TXMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TXMDTherapeuticsMD Announces First Quarter 2026 Financial Results
TherapeuticsMD has announced its financial results for the first quarter of 2026. However, the article does not provide specific details regarding the performance metrics or any significant developments related to the company's operations. The lack of detailed information limits the insight into the company's current standing.
Read more →TXMDTherapeuticsMD Announces Full Year 2025 Financial Results
TherapeuticsMD has announced its financial results for the full year 2025. The article provides an overview of the company's performance, but lacks detailed insights into specific financial metrics or strategic developments. Further analysis may be needed to understand the implications of these results on the company's future.
Read more →Competitive Position
How TXMD ranks across every disease it competes inCompetitive Position is a premium feature
See how TXMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial